Alzinova

Alzinova is a clinical-stage biotech focused on developing disease-modifying immunotherapies for Alzheimer's disease, one of the world's largest unmet medical needs. Its core differentiator is the AβCC Peptide™ platform, designed to precisely target toxic amyloid-beta oligomers, believed to be the primary drivers of neurodegeneration. The company has progressed its lead vaccine candidate, ALZ-101, into Phase 1b clinical trials and is publicly listed on Nasdaq First North Growth Market in Stockholm to fund its ambitious R&D. Alzinova's strategy hinges on validating its oligomer-specific hypothesis to potentially offer a safer and more effective therapeutic option than broader amyloid-targeting approaches.

The proprietary AβCC Peptide™ technology is designed to specifically stabilize and target neurotoxic amyloid-beta oligomers, enabling the development of both active (vaccine) and passive (antibody) immunotherapies for Alzheimer's disease.

Alzinova competes in the crowded Alzheimer's space but is differentiated by its focus on toxic amyloid-beta oligomers. It faces competition from approved plaque-binding antibodies (Biogen/Eisai, Eli Lilly), other next-generation amyloid-targeting biotechs, and a handful of active immunotherapy players. Its success hinges on proving its targeted approach offers clinical advantages over broader amyloid clearance.